Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel

Executive Summary

Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune for new molecular entities with priority review status in the last year, the consulting firm Parexel concludes in a new report

You may also be interested in...

Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race

Merck Serono's NDA filing will not prohibit a possible priority review for Novartis' oral FTY720, which had Phase III data released the same day; both applications face close scrutiny with less than ideal clinical trial packages.

An Easy Landing? Cephalon Scores Priority Review For Nuvigil In Jet Lag Disorder

Some, however, remain skeptical of the medicine's potential after the Provigil patent expires.

Industry Wants More Transparency From Agency On REMS Determinations

SAN DIEGO - Industry is hoping an upcoming Risk Evaluation and Mitigation Strategy guidance document will outline a more transparent process regarding the FDA's REMS decisions

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts